Bacteriophages, Critical Biocatalysts of Bacterial Doom: The Dawn of a New Era in the Fight against Multidrug Resistant Bacteria, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 2536
Special Issue Editor
Interests: structural and functional stabilization of protein entities; bacteriophages; transdermal drug delivery; phage-based biocontrol
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antimicrobial therapy using bacteriophage particles for controlling infections caused by multidrug-resistant bacteria in humans assumes a particular relevance in present times. Over the past few years, the world has witnessed a dramatic increase in bacterial resistance to available antibiotics, in such a way that humankind is practically facing a “new pre-antibiotic era”. According to the World Alliance Against Antibiotic Resistance (WAAAR) Organization, founded in 2012, currently available antibiotics may become totally ineffective in only a few years due to either irrational prescription and self-medication, together with their extensive use in agriculture, aquaculture, and veterinary practices. The need to develop feasible and safe alternatives to antibiotics is therefore critical. In this context, the use of strictly lytic bacteriophage particles assumes a particular relevance for the treatment of infections caused by multidrug-resistant bacteria. Beyond the therapeutic applications in humans, there is much more being done worldwide to control pathogenic bacteria using phages, especially those responsible for plant diseases, for diseases in fish and shellfish, and bacteria responsible for infections in animals, that we hope contributors like you will highlight the importance of bacteriophage-based biocontrol of pathogens for the preservation of all life forms. This Special Issue aims to collect original contributions (research articles and reviews) describing and reporting recent advances and developments in the field of bacteriophage-based antimicrobial strategies, either laboratory studies or clinical applications.
Potential topics include, but are not limited to:
- Strictly lytic bacteriophage particles;
- Determinants of bacteriophage host range;
- Phage-based biocontrol of pathogenic bacteria in humans;
- Phage-based biocontrol of phytopathogens in plants;
- Phage-based biocontrol of pathogenic bacteria in veterinary medicine;
- Phage-based biocontrol of pathogenic bacteria in aquaculture and mariculture;
- Synthetic bacteriophages;
- Computational analysis of bacteriophage genomic data;
- Mechanisms of bacterial resistance to bacteriophages;
- Predator-prey relationships in phage therapy;
- Transdermal permeation of bacteriophage particles.
Prof. Dr. Victor Manuel Balcão
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- strictly lytic bacteriophage particles
- phage-based control of phytopathogens
- phage therapy in humans, animals and fish
- bioinformatic tools for phage genomics
- resistance to bacteriophages
- anti-phage defense systems
- transdermal permeation of bacteriophage particles
